Ultra-low cholesterol poses no safety issues, analysis suggests

5d9cf6c8-8067-420e-ab59-562fa4b43927articleimage.jpg

29 Aug 2017 --- Aggressively reducing low-density lipoprotein cholesterol (LCL-C) to ultra-low levels poses no health risks, analysis of research has suggested. It was associated with progressively fewer cardiovascular events and no apparent safety concerns in patients with stable atherosclerotic cardiovascular disease over 2.2 years of follow-up, according to a new analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial.

The findings, presented at European Society of Cardiology (ESC) Congress on 27 August and published in The Lancet, “suggest that a lower LDL-C target – far below current guidelines – can safely be considered to further reduce the risk of recurrent cardiovascular events in high risk patients,” says investigator Dr. Robert Giugliano from Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, US.

“These findings are unique in that they represent the first analysis of a large cohort of patients to achieve such very low LDL-C levels, namely being less than one-third of the most common treatment goal of below 1.8 millimoles per liter (mmol/L) for highest risk patients,” he says.

Lowered levels
The FOURIER trial randomized patients with stable atherosclerotic cardiovascular disease and treated with background statin therapy, to either placebo or evolocumab – a proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody.

Initial results from the trial showed that evolocumab lowered LDL-C levels to a median of 0.8 mmol/L and significantly reduced the risk of cardiovascular events at a median follow-up of 2.2 years.

The new analysis examined efficacy and safety endpoints according to degree of LDL-C reduction at one month. In addition, a study known as EBBINGHAUS embedded within the larger analysis explored effects on cognition using a validated tablet-based tool.

A total of 25,982 patients with an LDL-C assessment at week 4 who did not experience a primary efficacy or pre-specified safety event prior to the week 4 visit were included in the analysis.

The study showed that the risk of the primary efficacy endpoint – a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization or hospitalization for unstable angina declined steadily as LDL-C levels decreased, with no significant association between LDL-C level and adverse events.

A similar reduction was observed in the key secondary endpoint, with 2,669 subjects in the lowest LDL-C category (below 0.5 mmol/L) at four weeks experiencing the lowest rate of cardiovascular death, or myocardial infarction compared to the group with highest LDL-C (above 2.6 mmol/L).

Exploratory analyses in a subgroup of 504 patients with an LDL-C lower than 0.25 mmol/L showed an even further reduction in cardiovascular events with no increase in safety events.

Additionally, among 1,154 patients who underwent formal cognitive testing prior to, or on the first day of study treatment as part of the EBBINGHAUS study, there were no adverse effects on memory, executive function, memory, or reaction time associated with lower LDL-C.

“Although longer-term follow-up will be important, the totality of evidence to date from trials of intensive lipid lowering supports reduction of LDL-C in high-risk patients to levels below those currently recommended in cholesterol guidelines,” notes Dr. Giugliano.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

GOS holds dietary fiber potential: FrieslandCampina eyes new applications

13 Aug 2018 --- FrieslandCampina is targeting the dietary fiber opportunity for its Galacto-Oligosaccharides (GOS). The move comes in response to the recent FDA green light on specific dietary fibers which presents new market opportunities and application areas. “There is a lot of interest in clean, green and label-friendly ingredients and fiber is one that they are looking for, but in good tasting applications. This really means a lot more flexibility for formulators to offer something that has both prebiotic and fiber benefits,” Sarah Staley of FrieslandCampina tells NutritionInsight on the topic of GOS as a trending prebiotic fiber.

Health & Nutrition News

Sodium guidelines under scrutiny: Only regions consuming over 5g a day should be targeted, concludes study

10 Aug 2018 --- A new study shows that for the vast majority of communities, sodium consumption is not associated with an increase in health risks except for those whose average consumption exceeds 5g/day (equivalent to 12.5g of salt, or 2.5 teaspoons). Communities with high average levels of sodium intake (above 5g/day) were mostly seen in China, with only about 15% of communities outside China exceeding this level of consumption. 

Health & Nutrition News

Metabolic syndrome scores: Gender differences in low-calorie diet benefits

08 Aug 2018 --- A low-calorie diet causes different metabolic effects in women than in men, a new Diabetes, Obesity and Metabolism study suggests. In the study of more than 2,000 overweight individuals with pre-diabetes who followed a low-calorie diet for 8 weeks, men lost significantly more body weight than women, and they had larger reductions in a metabolic syndrome score, a diabetes indicator, fat mass and heart rate. 

Business News

Raisio looks to Benecol brand growth amid company “renewal”

08 Aug 2018 --- Raisio is targeting renewed growth for its “star” international brand Benecol, with an increased focus on marketing products featuring the cholesterol-lowering plant stanol esters. The strategy includes a €2 million (US$2.3 million) marketing investment in the brand during Q2 and the opening of a new entity to serve the strong Irish market, as well as the launch of product innovations, including a new cereal bar line which uses the ingredient.

Health & Nutrition News

Study: Deep ocean water proven effective for weight management

31 Jul 2018 --- Deep sea water, which is filled with minerals, can exhibit anti-obesity effects, a study published in Marine Drugs has found, by regulating lipolysis, fatty acid oxidation and inflammation in rats fed a high-fat diet. The material used in the study was D-minneralz – which contains over 70 kinds of minerals and trace elements – from the Taiwan Yes Deep Ocean Water Company.

More Articles
URL : http://www.nutritioninsight.com:80/news/ultra-low-cholesterol-poses-no-safety-issues-analysis-suggests.html